AbbVie wards off another Humira biosim challenger with Fresenius Kabi settlement

In a Humira patent deal with AbbVie, Fresenius Kabi will have to pay undisclosed royalties and can launch its biosim in Europe upon approval. In the U.S., the company will have to wait until September 2023 until it can launch.